DSpace Repository

Roles of pyridine and pyrimidine derivatives as privileged scaffolds in anticancer agents

Show simple item record

dc.contributor.author Prachayasittikul S.
dc.contributor.author Pingaew R.
dc.contributor.author Worachartcheewan A.
dc.contributor.author Sinthupoom N.
dc.contributor.author Prachayasittikul V.
dc.contributor.author Ruchirawat S.
dc.contributor.author Prachayasittikul V.
dc.date.accessioned 2021-04-05T03:23:12Z
dc.date.available 2021-04-05T03:23:12Z
dc.date.issued 2017
dc.identifier.issn 13895575
dc.identifier.other 2-s2.0-85025119431
dc.identifier.uri https://ir.swu.ac.th/jspui/handle/123456789/13308
dc.identifier.uri https://www.scopus.com/inward/record.uri?eid=2-s2.0-85025119431&doi=10.2174%2f1389557516666160923125801&partnerID=40&md5=8579905d52458c712981439463f18b4a
dc.description.abstract Background: Cancer has been considered to be a global health concern due to the impact of disease on the quality of life. The continual increase of cancer cases as well as the resistance of cancer cells to the existing drugs have driven the search for novel anticancer drugs with better potency and selectivity, improved pharmacokinetic profiles, and minimum toxicities. Pyridine and pyrimidine are presented in natural products and genetic materials. These pyridine/pyrimidine core structures have been noted for their roles in many biological processes as well as in cancer pathogenesis, which make such compounds become attractive scaffolds for discovery of novel drugs. Results & Conclusion: In the recent years, pyridine- and pyrimidine-based anticancer drugs have been developed based on structural modification of these core structures (i.e., substitution with moieties and rings, conjugation with other compounds, and coordination with metal ions). Detailed discussion is provided in this review to highlight the potential of these small molecules as privileged scaffolds with attractive properties and biological activities for the search of novel anticancer agents. © 2017 Bentham Science Publishers.
dc.subject 1,2,3 triazole derivative
dc.subject 1,4 naphthoquinone
dc.subject 2,4 diphenoxy 6 aryl pyridine
dc.subject 2,4 diphenoxy pyridine
dc.subject 2,4 diphenoxyl 6 heteroaryl pyridine
dc.subject 2,4 diphenyl 6 aryl pyridine
dc.subject 2,4 diphenyl 6 heteroaryl pyridine
dc.subject 2,4,6 triheteroaryl pyridine
dc.subject 2,4,6 triphenyl pyridine
dc.subject 2,6 diaminopyridine
dc.subject 2,6 diphenyl 4 heteroaryl pyridine
dc.subject 3 aminopicolinaldehyde thiosemicarbazone
dc.subject 3 aminopyridine thiosemicarbazone
dc.subject 3,5 disubstituted pyridine
dc.subject 4 chromanone derivative
dc.subject anthranilic acid
dc.subject antineoplastic agent
dc.subject coumarin
dc.subject doxorubicin
dc.subject isoflavone
dc.subject nicotinamide
dc.subject picoline derivative
dc.subject pyridine derivative
dc.subject pyrimidine derivative
dc.subject quinoline
dc.subject ribonucleotide reductase
dc.subject tetrahydroisoquinoline
dc.subject thiadiazole derivative
dc.subject thiosemicarbazone derivative
dc.subject unclassified drug
dc.subject unindexed drug
dc.subject antineoplastic agent
dc.subject pyridine derivative
dc.subject pyrimidine derivative
dc.subject A-549 cell line
dc.subject antineoplastic activity
dc.subject antiproliferative activity
dc.subject apoptosis
dc.subject breast cancer
dc.subject cancer cell
dc.subject cancer therapy
dc.subject cell growth
dc.subject cell survival
dc.subject chronic myeloid leukemia
dc.subject colorectal cancer
dc.subject DNA repair
dc.subject erectile dysfunction
dc.subject Hep-G2 cell line
dc.subject IC50
dc.subject kidney carcinoma
dc.subject neoplasm
dc.subject non small cell lung cancer
dc.subject nonhuman
dc.subject prostate cancer
dc.subject quality of life
dc.subject Review
dc.subject tumor suppressor gene
dc.subject chemistry
dc.subject DNA damage
dc.subject drug effects
dc.subject human
dc.subject structure activity relation
dc.subject synthesis
dc.subject Antineoplastic Agents
dc.subject Cell Survival
dc.subject DNA Damage
dc.subject Humans
dc.subject Pyridines
dc.subject Pyrimidines
dc.subject Structure-Activity Relationship
dc.title Roles of pyridine and pyrimidine derivatives as privileged scaffolds in anticancer agents
dc.type Review
dc.rights.holder Scopus
dc.identifier.bibliograpycitation Mini-Reviews in Medicinal Chemistry. Vol 17, No.10 (2017), p.869-901
dc.identifier.doi 10.2174/1389557516666160923125801


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics